Decibel Therapeutics Inc expected to post a loss of 56  cents a share - Earnings Preview

Decibel Therapeutics

10/05/2022 03:01

* Decibel Therapeutics Inc  DBTX.OQ   DBTX.O  is expected
to show
no change in quarterly revenue when it reports  results on May
11 (estimated). 
    * ​Refinitiv's mean analyst estimate for Decibel
Therapeutics Inc
is for a loss of 56 cents per share. For the same quarter last
year, the company reported a loss of $1.09 per share.
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Decibel
Therapeutics Inc is $18​, above​ its last closing price
of $1.85. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.23       -0.47      -0.49     Missed  -3.2
 Sep. 30 2021  -0.44       -0.43      -0.59     Missed  -36.6
 Jun. 30 2021  -0.41       -0.37      -0.47     Missed  -26.4​
 Mar. 31 2021  -0.54       -0.54      -1.09     Missed  -102.2
 ​​                                                     
                                                        ​
 This summary was machine generated May 10 at 02:01 GMT.  All
figures in US dollars  unless otherwise stated